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Abstract: Naturally occurring dietary agents present in a wide variety of plant products, are rich
sources of phytochemicals possessing medicinal properties, and thus, have been used in folk medicine
for ages to treat various ailments. The beneficial effects of such dietary components are frequently
attributed to their anti-inflammatory and antioxidant properties, particularly in regards to their
antineoplastic activities. As many tumor types exhibit greater oxidative stress levels that are
implicated in favoring autonomous cell growth activation, most chemotherapeutic agents can
also enhance tumoral oxidative stress levels in part via generating reactive oxygen species (ROS).
While ROS-mediated imbalance of the cellular redox potential can provide novel drug targets,
as a consequence, this ROS-mediated excessive damage to cellular functions, including oncogenic
mutagenesis, has also been implicated in inducing chemoresistance. This remains one of the
major challenges in the treatment and management of human malignancies. Antioxidant-enriched
natural compounds offer one of the promising approaches in mitigating some of the underlying
mechanisms involved in tumorigenesis and metastasis, and therefore, have been extensively explored
in cancer chemoprevention. Among various groups of dietary phytochemicals, polyphenols have
been extensively explored for their underlying chemopreventive mechanisms in other cancer models.
Thus, the current review highlights the significance and mechanisms of some of the highly studied
polyphenolic compounds, with greater emphasis on pancreatic cancer chemoprevention.
Keywords: dietary polyphenols; antioxidants; reactive oxygen species; cellular signaling pathways;
pancreatic cancer chemoprevention; chemotherapeutic agents
1. Introduction
Natural dietary polyphenolic compounds are widely distributed in various plant sources and
have been explored against several health-related ailments and their associated symptoms, due to
their medicinal properties [1–6]. Polyphenols constitute a large family of phytochemicals, present in a
wide variety of fruits, vegetables, flowers, and leaves [7–11]. Epidemiological studies also support
the fact that consumption of a natural polyphenol-enriched diet could reduce the incidence or lower
the risk of pathophysiologies including cardiovascular diseases [12–16]. However, other reports
have documented contrasting or inconsistent evidence for polyphenols intake against cardiovascular
diseases and cancer [17–20]. This indicates the need for conducting further randomized controlled
trials and observational or behavioral studies in human subjects with such disease conditions [17–20].
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Nevertheless, experimental studies have characterized that polyphenolic derivatives, including
quercetin, resveratrol, etc., possess several medicinal properties, including anti-inflammatory and
antioxidant activities, and therefore, have been extensively explored for cancer chemoprevention in
various cancer models including pancreatic cancer [7–11,21].
It is well established that reactive oxygen species (ROS) attribute several modifying roles in various
inflammatory and chronic diseases including cancer [22–24]. Under normal circumstances, the redox
status of the cells is maintained by homeostasis between ROS production, and its sequestration
by antioxidants [22]. While ROS generation is essential to host innate immune responses against
extracellular pathogens, including bacterial and viral infections, its exacerbated production causes
an imbalance in the cellular redox potential, leading to alterations in the signaling cascades [25–27].
Depending upon the type/nature of pro-oxidative stressors, or the changes in the autonomous cellular
conditions along with the cell types, the perturbation in ROS generation of any origin (i.e., governed
by various cellular compartments) have been linked with neocarcinogenesis [28–32]. Importantly,
to overcome or mitigate such ROS-mediated events, multiple cellular antioxidant enzymes and
redox proteins, including superoxide dismutase and thioredoxin, have been shown to serve as the
crucial counteracting antioxidant defense systems [30,33]. As cancer cells, particularly the tumor
microenvironment, exhibit higher basal levels of oxidative stress compared to the normal cells,
increased levels of antioxidant defenses have been observed to circumvent ROS-mediated tumor cell
damage [30,34,35]. Although most ROS-generating therapeutic agents have been documented to act as
prooxidant redox modifiers and designed to target the impaired or upregulated redox machinery of
tumor cells, such tumor-eradicating mechanisms have also been hypothesized and demonstrated to
induce chemoresistance [36,37].
Despite recent advances in treatment modalities, including immunotherapy approaches, most
chemotherapeutic agents are still the mainstay to treat a variety of cancers either alone, or in combination
with other drugs (e.g., repurposing drugs, targeted therapy) [38–40]. However, mutations/aberrations
in the cellular signaling pathways that mediate chemotherapy-ROS-induced tumor resistance result
in either reduced treatment efficacy or tumor relapse after an initial anti-tumor response [41,42].
Therefore, most chemotherapeutic drugs are not considered good treatment options as a single agent for
advanced-stage/metastatic cancers. As these adverse events pose one of the critical ongoing challenges
in cancer treatment, several new therapeutic strategies are being considered and implemented. Natural
dietary polyphenols have been examined to explore their synergy with therapeutic agents in preclinical
experimental models. Given that the underlying chemopreventive mechanisms of polyphenolic
compounds have been reviewed in other cancer models, the current review highlights the significance
of some of the highly explored polyphenols in pancreatic cancer chemoprevention.
2. Polyphenol-Enriched Dietary Compounds in Pancreatic Cancer Chemoprevention
Since the focus of this review is to highlight the significance of naturally occurring dietary
polyphenols (Figure 1), given that they have not only been extensively explored for in-depth mechanistic
insights, but also widely available for consumption, we excluded studies on synthetic derivatives or
modified compounds of such polyphenols.
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Figure 1. Structural representations of polyphenols. 
3. Quercetin 
The flavonoid quercetin (i.e., quercetin glucosides in its natural form) has been widely explored 
for its antineoplastic activities in various cancer models, including pancreatic cancer [43–50]. 
Evidence supporting its chemopreventive properties includes studies demonstrating that treatment 
of quercetin decreased the viability or proliferation of in vitro pancreatic cancer cell lines such as 
PANC-1, BxPC-3, and MiaPaCa-2 in a dose- and/or time-dependent manner [51,52]. When combined 
with the standard chemotherapeutic agents such as 5-fluorouracil [5-FU] or gemcitabine, growth 
suppression of pancreatic cancer cell lines were either found to be enhanced or relatively unchanged 
compared to monotherapy, indicating that quercetin may sensitize chemotherapy efficacy depending 
upon the cell lines used [51,52]. Figure 2 depicts mechanisms involved in quercetin-mediated 
chemoprevention, including its ability to enhance the sensitivity or efficacy of chemotherapeutic 
effects. Notably, changes in the cellular morphological features such as cell condensation, nuclear 
fragmentation, impaired mitochondrial membrane potential, intracellular Ca2+ accumulation, and cell 
cycle arrest have been noted in quercetin-exposed pancreatic cancer cell lines. These cellular 
modifications have been shown to induce apoptosis, measured by increased caspase-3 or 9 activity, 
or annexin V and propidium iodide staining by flow cytometry, or increased expression of the pro-
apoptotic protein Bak or decreased expression of anti-apoptotic protein Bcl-xl assessed by western 
blotting [51,52]. Mechanistically, induction of endoplasmic reticulum (ER) stress pathways such as 
higher protein expression of GADD153/CHOP causing increased Grp78/Bip protein, as well as ERK 
activation were observed by quercetin treatment [52]. In another report, oral administration of 
quercetin has been found to significantly suppress the growth of orthotopically implanted pancreatic 
tumor xenografts compared to non-treated mice [53]. However, no additive effects were observed by 
quercetin in enhancing gemcitabine efficacy [53]. Quercetin-mediated inhibition of pancreatic tumor 
growth was accompanied by reduced tumoral BrdU, and TUNEL staining, which are the suggestive 
markers of decreased proliferation and increased apoptosis of tumor cells [53]. Overall, these findings 
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and MiaPaCa-2 in a dose- and/or time-dependent manner [51,52]. When combined with the standard
chemotherapeutic agents such as 5-fluorouracil [5-FU] or gemcitabine, growth suppression of pancreatic
cancer cell lines were either found to be enhanced or relatively unchanged compared to monotherapy,
indicating that quercetin may sensitize chemotherapy efficacy depending upon the cell lines used [51,52].
Figure 2 depicts mechanisms involved in quercetin-mediated chemoprevention, including its ability
to enhance the sensitivity or efficacy of chemotherapeutic effects. Notably, changes in the cellular
morphological features such as cell condensation, nuclear fragmentation, impaired mitochondrial
membrane potential, intracellular Ca2+ accumulation, and cell cycle arrest have been noted in
quercetin-exposed pancreatic cancer cell lines. These cellular modifications have been shown to
induce apoptosis, measured by increased caspase-3 or 9 activity, or annexin V and propidium iodide
staining by flow cytometry, or increased expression of the pro-apoptotic protein Bak or decreased
expression of anti-apoptotic protein Bcl-xl assessed by western blotting [51,52]. Mechanistically,
induction of endoplasmic reticulum (ER) stress pathways such as higher protein expression of
GADD153/CHOP causing increased Grp78/Bip protein, as well as ERK activation were observed
by quercetin treatment [52]. In another report, oral administration of quercetin has been found to
significantly suppress the growth of orthotopically implanted pancreatic tumor xenografts compared
to non-treated mice [53]. However, no additive effects were observed by quercetin in enhancing
gemcitabine efficacy [53]. Quercetin-mediated inhibition of pancreatic tumor growth was accompanied
by reduced tumoral BrdU, and TUNEL staining, which are the suggestive markers of decreased
proliferation and increased apoptosis of tumor cells [53]. Overall, these findings indicated the promising
chemopreventive effects of quercetin in in vitro and in vivo pancreatic cancer models.
An active area of research in preclinical models is to determine whether the bioavailability of
orally or intraperitoneally administered quercetin results in sufficient systemic concentrations that
could result in a sustained anti-tumoral activity. In the intestine, quercetin undergoes hydrolysis
by lactase phlorizin hydrolase, resulting in subsequent diffusion as quercetin aglycones are actively
transported by sodium-dependent glucose transporter, and then, subsequent deglycosylation by
cytosolic β-glucosidase [54]. Studies by Zhang et al. evaluated the uptake of quercetin in MiaPaCa-2
pancreatic cancer cells in vitro, as well as its in vivo distribution in murine pancreatic tumor xenografts,
plasma, lung, liver and pancreas [55]. The authors demonstrated that following treatment with 30 µM
Antioxidants 2020, 9, 651 4 of 20
quercetin, it quickly accumulates in MiaPaCa-2 cells at nmol/mg protein concentration within 30 min,
but its level decreases gradually in a time-dependent manner [55]. Similarly, nude mice harboring
orthotopic MiaPaCa-2 tumor xenografts, and fed with 0.2% or 1% or 5% quercetin in an AIN93G-based
diet for a period of 6–8 weeks, have found to exhibit varying levels of quercetin and its metabolite
isorhamnetin in plasma and tumors, as well as in liver, lung and pancreas, which indicates its effective
absorption [55]. While cotreatment of gemcitabine (120 mg/kg per mouse, i.p.) with quercetin (1%)
has been found to result in significantly decreased growth of pancreatic tumors, gemcitabine reduced
quercetin absorption in the circulatory system and liver, but not in other tissues [55]. These studies
suggested that quercetin gets readily metabolized and bioavailable to exert a systemic anti-tumoral
effect as well as augments chemotherapy efficacy. However, further studies are warranted to verify
whether or not quercetin can also enhance the metabolism and absorption of chemotherapy agents.Antioxidants 2020, 9, x FOR PEER REVIEW 4 of 21 
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In another report, the authors determined the interaction of apigenin with GSK3β [121]. 
Molecular docking studies predicted that apigenin binds within the GSK3β cavity with low 
interaction energies, which leads to the inhibiti n of its enzymatic activity [121]. Similar results were 
observed with other flavonoids such as quercetin and luteolin, indicating their potential in targeting 
GSK3β signaling to suppress pancreatic cancer. Apigenin has also been shown to induce G2/M cell 
cycle arrest and apoptosis in BxPC-3 and PANC-1 pancreatic cancer cell lines via targeting 
GSK3β/NF-kB signaling cascade [122]. Increased expression of cytokines (including the IL17 family, 
LTA and INFB1) was correlated with increased apigenin-induced apoptosis [122]. Given the critical 
roles of NF-kB in cancer progression, studies by Wu et al. determined the regulatory mechanism of 
NF-kB in the context of apigenin [123]. Apigenin treatment decreased cell survival and increased 
apoptosis of AsPC-1, PANC-1 and Mi PaCa-2 pan reatic cancer cell ines through the inhibition of 
tumor necrosis factor-alpha (TNFα)-induced DNA binding (p65 and p50 subunits), resulting in 
reduced transcriptional activities of NF-kB [123]. Decreased NF-kB activity was associated with IkBα 
degradation, reduced expression, and activation of upstream IKK (α and β subunits), and reduced 
NF-kB nuclear translocation [123]. Notably, the NF-kB inhibitor Bay11-7082 enhanced the 
chemosensitivity of apigenin, and IKKβ overexpression attenuated apigenin-induced decreased cell 
survival. Importantly, suppression of AsPC-1 tumor growth by apigenin was also correlated with 
decreased protein expression and phosphorylation of IKKα/β and increased apoptosis [123]. These 
findings indicated that apigenin targets IKK-mediated NF-kB activation to inhibit pancreatic cancer 
growth. From these studies, it can be postulated that apigenin could be explored in combination with 
the pharmacological inhibitors of these pathways/targets in widely used transgenic experimental 
pancreatic cancer models. 
5.1. Other Cellular Targets of Apigenin 
denotes inhibition or suppression.
S veral cellular mecha isms by which quercetin treatme t inhibits th growth of pancreatic cancer
cell lines in in vitro and in vivo models, have been identified. The authors have also explored
the cellular model systems to test the sensitivity or resistance to agents, to further define the
transl tional sig ificance of qu rceti to be sed in combination treatment approach for pancreatic
cancer. In one such study, Borska et al. determined the effects of quercetin on the daun ru icin
sensitive EPP85-181P c ll line, as well as the d unorubicin resistant EPP85-181RDB cell line [56].
Quercetin exposure wa found to reduce cell proliferation and increas apoptosis in both the cell
lines in a dose- ependent mann r. Importantly, quercetin co bined wit daunorubicin induced
synergistic effects in daunorubicin-sensitive cells, and also, sensitized the daunorubicin-re istant cells
to daunorubicin cytotoxic effe ts [56]. Another report by the same group later identified the role of
P-glyc protein (ABCB1), one of the ABC transporters reported to induce chemoresistance via its ability
to expel drugs outside of cells [57]. In this study, the aut ors determi ed P-glyc pr tei was involved
in th bility of querc tin to promote daunorubicin-induced c t toxicity in both daunorubicin-resistant
EPP85-181RDB and daunorubicin sensitive EPP85-181P cell lines [57]. They demonstrated that
P-glycoprotein expression was 51-fold higher in the resistant cells compared to the sensitive cells
and that quercetin treatment decreas d P-glycoprotei expression by 35% in the resistant cell line
and by 67% in the sensitive cell line [57]. These findings indicated that quercetin possesses the
ability to overcome tumor resistance mechanisms, and thus, could be used to enhanc the efficacy of
chemotherapeutic agents.
Antioxidants 2020, 9, 651 5 of 20
3.1. Effects of Quercetin on Pancreatic Cancer Stem Cells and EMT
Targeting pancreatic cancer stem or stem-like cells (PCSCs) has been explored as a promising
approach to regulate the aggressiveness and metastatic ability of tumor cells [58,59]. In this regard,
quercetin treatment has been shown to reduce PCSCs’ ability to induce in vitro spheroid/colony
formation, or in vivo growth of stem-cell enriched tumor xenografts [60]. These effects were mediated
via mechanisms involving diminishing ALDH1 activity, preventing epithelial to mesenchymal transition
(EMT), reducing tumor cell angiogenesis, induction of apoptosis, as well as decreased expression of
CSCs markers [60]. Importantly, these quercetin-mediated effects were enhanced by the combination of
another dietary isothiocyanate compound, sulforaphane. Overall, the data suggested that additive or
synergistic chemopreventive effects could be achieved with the use of more than one natural compound
possessing similar mechanisms of action.
Another study utilized a culture sphere model of PCSCs along with their respective parental
cells to determine the interaction and underlying mechanisms of quercetin-mediated inhibition of
PCSCs [61]. The studies identified increased expression of β-catenin in the parental cells compared to
PCSCs. In contrast, PCSCs exhibited increased resistance to gemcitabine compared to parental cells [61].
Importantly, quercetin treatment resulted in decreased proliferation, invasion, and sphere-forming
capacity of PCSCs, and also, reduced the expression of CSCs markers [61]. Notably, these effects
were found to be associated with the alterations in β-catenin expression, and that quercetin combined
with gemcitabine not only reduced the growth of PCSCs but also their inherent chemoresistance to
gemcitabine [61]. These findings indicated the potential of targeting β-catenin to improve gemcitabine
efficacy against pancreatic cancer.
In another report, quercetin treatment has been shown to suppress the growth of PANC-1 and
PATU-8688 pancreatic cancer cell lines via inhibiting EMT and decreasing the secretion of matrix
metalloproteinase (MMP) [62]. These quercetin-induced effects were found to be mediated via
mechanisms involving the reduced activation and activity of signal transducer and activator of
transcription 3 (STAT3) [62]. To verify this mechanism, the authors demonstrated that quercetin
blocked IL-6-induced STAT3 activation, EMT and MMP secretion that resulted in increased migration
and invasion of pancreatic cancer cell lines [62]. These findings also indicate that inhibition of such
pathways with resveratrol can result in higher chemopreventive effects in pancreatic cancer.
3.2. Quercetin and MicroRNA
Given that the altered expression of microRNAs (miRs) have been documented in clinical samples,
they have been extensively studied for their roles in modulating cancer growth and the efficacy of
therapeutic agents in tumor models that include pancreatic cancer [63–65]. Nwaeburu et al. performed
miRs profiling in PDA cells with or without quercetin treatment and identified miR let-7c as one of
the highly upregulated miRs following quercetin treatment [66]. The authors also identified NUMB
like endocytic adaptor protein (NUMBL), a Notch inhibitor as a target of let-7c. Similar to quercetin,
transfection of let-7c mimics induced a wildtype construct of NUMBL 3′UTR, its mRNA and protein
expression, but inhibited Notch protein expression [66]. The in vitro transfection or in vivo intravenous
injection of let-7c resulted in the inhibition of colony formation, wound healing, and cell proliferation,
or decreased mass of PDA tumor in the fertilized check egg model [66]. These findings suggested that
quercetin-induced let-7c serves as a novel mechanism for suppressing pancreatic tumor growth [66].
This idea is further supported by increased expression of miR-let7-a by quercetin and other dietary
agents in pancreatic cancer models but not in normal cells, and that miR-let7-a induction was found to
be associated with K-ras inhibition [67]. The combination of quercetin with sulforaphane or green tea
catechins complemented each other and resulted in enhanced inhibition of PDA progression. This effect
was found to be mediated via miR-let7-a induction and K-ras inhibition [67]. Given these findings,
one can extrapolate that miR-let7-a expression could be used to assess the efficacy of quercetin against
pancreatic cancer.
Antioxidants 2020, 9, 651 6 of 20
Importantly, bioinformatics tools and database analysis have also been explored to predict the new
mechanisms and targets of quercetin in cancer models, including pancreatic cancer [68]. Of various targets,
CD36 and thrombospondin-1 were identified to be targeted by quercetin in pancreatic cancer [68].
3.3. Quercetin Effects on Chemotherapy Efficacy
Given the improved effectiveness of quercetin when combined with other dietary agents [60,67],
quercetin has been tested for its ability to enhance the sensitivity of chemotherapeutic agents. In one
such study, Kim et al. have found that quercetin combined with tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL), an anticancer agent, augmented TRAIL-induced apoptotic response
in TRAIL-resistant pancreatic cancer cells [69]. These effects were mediated via mechanisms involving
c-Jun N-terminal kinase (JNK), FLICE-like inhibitory protein (cFLIP), and BH3-only pro-apoptotic
protein BID [69]. Additional studies demonstrated that the activation of JNK, overexpression of cFLIP,
or BID knockdown rescued pancreatic cancer cells to TRAIL and quercetin-induced apoptosis [69].
As the receptor for advanced glycation end products (RAGE) expression has been implicated in
inducing gemcitabine resistance, a study led by Lan et al. tested if quercetin can enhance gemcitabine
sensitivity via targeting RAGE in gemcitabine-resistant pancreatic cancer cells [70]. The authors
demonstrated that quercetin treatment downregulated RAGE expression, which resulted in cell cycle
arrest, autophagy and apoptosis induction. These effects were mediated via the inhibition of the
PI3K/AKT/mTOR pathway, which resulted in enhanced gemcitabine sensitivity in gemcitabine-resistant
pancreatic cancer cells [70]. Overall, these findings suggested that quercetin due to its ability to target
a wide array of signaling pathways could be used as a promising combination approach to enhance
the efficacy of chemotherapy agents against pancreatic cancer.
4. Resveratrol
Similar to quercetin, another polyphenol resveratrol (trans-3,5,4′-trihydroxystilbene) is widely
distributed in various fruits and has been characterized due to its powerful antioxidant property
in various disease models, including cancers [71–76]. Importantly, resveratrol has been extensively
studied to understand the mechanisms of its anti-proliferative and anti-carcinogenic properties that
induce programmed cell death (i.e., apoptosis) [77–79]. Figure 3 depicts mechanisms involved in
resveratrol-mediated chemoprevention, including its ability to enhance the sensitivity or efficacy
of gemcitabine chemotherapy. A study done by Cui et al. has shown that resveratrol treatment
inhibited the proliferation of pancreatic cancer cell lines, PANC-1, BxPC-3, and AsPC-1 in a dose- and
time-dependent manner [80]. These findings along with other studies have found that resveratrol was
able to reduce colony formation or promote apoptosis by increasing the expression of pro-apoptotic
proteins such as Bax and caspase-3 while inhibiting the expression of anti-apoptotic proteins such as
Bcl-2, and Bcl-xL, as well as metalloenzymes such as leukotriene A4 hydrolase (LTA4H) [80,81]. Another
study has shown that resveratrol’s pro-apoptotic activity includes the involvement of the mitochondrial
pathway [82]. The experimental findings revealed that resveratrol treatment resulted in depolarization
of mitochondria membrane potential (consistent with mitochondrial dysfunction), leading to increased
apoptosis as measured by Annexin V/PI staining [82]. Similar pro-apoptotic mechanisms for resveratrol
have been identified in other tumor models such as lung, prostate, and colorectal cancers [83–85].
In another study, Garcia-Sanchez et al. have shown that resveratrol stimulates intracellular Ca2+
mobilization by inducing JNK activation, and this resulted in decreased viability of AR42J pancreatic
cancer cells [86]. In addition, resveratrol-induced cell cycle arrest or apoptosis in PANC-1, MIAPaCa-2,
Hs766T and AsPC-1 cell lines were found to be mediated via the activation of forkhead (FOXO) family of
transcription factors, and upregulation of FOXO target genes such as cyclin D1, p21/CIP1, p27/KIP1 and
Bim, as well as cleaved caspase-3 [87]. These changes also resulted in reduced phosphorylation of ERK,
PI3K, AKT, FOXO1 and FOXO3a [87]. Overall, these findings indicated that there are involvements of
a wide array of cellular signaling pathways in mediating chemopreventive effects of resveratrol in
pancreatic cancer.
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4.1. Other Cellular Targets of Resveratrol
In addition, the inhibition of the hedgehog signaling pathway, as well as decreased protein levels
of other family members or transcript expression of downstream target genes (i.e., Gli1, Ptc1, Smo,
CCND1 and BCL-2) were observed by resveratrol treatment [88]. These mechanistic changes resulted
in G0/G1 cell cycle arrest, and increased apoptosis in PANC-1, AsPC-1 or BxPC-3 pancreatic cancer cell
lines [88]. Moreover, resveratrol-mediated a dose- and time-dependent decrease in cellular proliferation,
and induction of apoptosis, in the Mia PaCa-2 pancreatic cancer cell line [89]. This was found to be
mediated via the inhibition of the hedgehog signaling pathway, and downregulation of protein and
mRNA expression of Ihh, Ptch, and Smo genes [89]. Moreover, resveratrol has also been found to
downregulate the mRNA expression of miR-21, and protein expression of glycogen synthase kinase
3 beta (GSK3β), while upregulation of the protein and mRNA levels of the growth factor, vascular
endothelial growth factor B (VEGF-B), was observed [90,91]. These mechanistic changes induced
increased expression of the pro-apoptotic Bax protein and decreased expression of the anti-apoptotic
Bcl-2 protein, which resulted in enhanced apoptosis in PANC-1, CFPAC-1, MiAPaCa-2 and Capan-2
pancreatic cancer cell lines [90,91]. Importantly, overexpression of miR-21 has been found to reverse
Bcl-2 protein downregulation, and apoptosis induction by resveratrol [90]. Similarly, VEGF-B silencing
via the siRNA approach has been reported to upregulate GSK3β protein expression and increase
the rate of apoptosis [91]. Importantly, the resveratrol combination resulted in a significantly higher
apoptotic rate compared to VEGF-B silencing or resveratrol alone treatments [91]. These findings also
indicate that inhibitors of these cellular targets could be explored with resveratrol to achieve higher
chemopreventive effects in pancreatic cancer.
4.2. Effects of Extracellular Environments on Resveratrol’s Chemopreventive Responses
The generation of ROS along with extracellular environmental factors have been studied in
various cancer models due to their ability to affect multiple cellular signaling pathways that can
modify the functionality of critical pro- and anti-apoptotic genes [92–94]. These morphological
and physiological changes not only help support cancer cells’ survival but also favor their invasive
capabilities [94–96]. A study by Shamim et al. explored resveratrol’s effects in low pH environments
for tumors that prefer specific acidic environments [96]. The studies demonstrated that the ability of
resveratrol to inhibit the growth and to induce internucleosomal DNA fragmentation-induced apoptosis
was enhanced at lower pH in Capan-2 and Panc-28 pancreatic cancer cell lines [96]. Subsequently,
other studies have also examined resveratrol’s effects on pancreatic cancer cells under two different
extracellular environmental (i.e., hyperglycemic and hypoxic) conditions [97,98]. One study involving
the extracellular hyperglycemic environment showed that it was able to induce cell cycle arrest in
PANC-1 cell line via inhibiting urokinase plasminogen activator (uPA), E-cadherin, and glucose
transporter 1 (GLUT1) expression. These changes resulted in the suppression of ERK and p38 MAPK
signaling pathways, as well as the transcription factor NF-κB [97]. Another study involving the
extracellular hypoxic environment revealed that resveratrol mediated cell cycle arrest in BxPC-3 and
PANC-1 cell lines through its ability to suppress hypoxia-inducible factor-1 alpha (HIF-1α), uPA
and MMP-2 protein expression, as well as inhibiting hypoxia-mediated activation of the hedgehog
signaling pathway [98]. Since ROS produced by cigarette smoking (CS) can also increase cancer
risk, a study explored the effects of resveratrol under this extracellular environment and found that
resveratrol was able to suppress CS-induced increased cellular proliferation of pancreatic cancer cells
via downregulating pERK expression [99]. Overall, these studies suggested that resveratrol was able
to mitigate extracellular environment-induced growth-enhancing effects on pancreatic cancer cells.
4.3. Effects of Resveratrol on Pancreatic Cancer Stem Cells and EMT
Resveratrol has also been examined for its ability to regulate EMT, which is involved in tissue
repair but has also been implicated in contributing to the progression of cancer [100–102]. Cancer
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cells that acquire mesenchymal features also develop the ability to escape from the primary tumor
site and metastasize to other organs [103]. Thus, the regulation of this mechanism has become a
focal point in cancer research. In an investigation of how resveratrol alters EMT regulation using
BxPC-3 and PANC-1 pancreatic cancer cell lines, it was found that resveratrol inhibits the cellular
proliferation, migration, and invasion in a dose-dependent manner via targeting the expression
of EMT-related genes such as E-cadherin, N-cadherin, vimentin, MMP-2 and MMP-9, as well as
PI3K/Akt/NF-κB signaling pathways [104]. Notably, studies have also been directed to define
resveratrol’s anti-cancerous characteristics with EMT within pancreatic cancer stem cells (PCSCs)
possessing stem cell ability. One study found that resveratrol can inhibit PCSCs characteristics by
inhibiting pluripotency maintaining factors such as Nanog, Sox-2, c-Myc and Oct-4, as well as the drug
resistance gene, ABCG2, in CSCs possessing CD133 + CD44 + CD24 + ESA + phenotype. These findings
were found to be associated with the suppression of migration and invasion, as well as EMT markers
such as Zeb-1, Slug, and Snail [105]. Another study reported that CD133 + PCSCs exhibit a significant
reduction in ACTA-2, IL-1β and N-cadherin immunoreactivities by resveratrol treatment [106]. These
findings implicated that resveratrol could be used to prevent EMT in pancreatic cancer cells.
4.4. Resveratrol Effects on Chemotherapy Efficacy
As combination chemotherapy approaches are being considered as promising strategies for cancer
treatment [107,108], several studies have explored the effectiveness of resveratrol in combination with
chemotherapeutic agents or other natural compounds. One possible reason for this is that while
ongoing therapeutic regimens aid marginal survival benefits, patients often experience tumor relapse,
and their tumors become more resistant to the identical treatment options [109]. Given that resveratrol
alone can decrease cellular proliferation by inducing G1 cell cycle arrest, cyclin D1 downregulation,
and inactivation of AKT-GSK3β and ERK1/2 signaling [110], other studies have shown that resveratrol
combined with gemcitabine chemotherapy is promising as a potential therapeutic option against
pancreatic cancer [111–114]. Jiang et al. have demonstrated that resveratrol treatment enhanced
the sensitivity of pancreatic cancer cells to gemcitabine via inducing AMP-activated protein kinase
(AMPK) signaling, resulting in the induction of yes-associated protein (YAP) cytoplasmic retention,
and the inhibition of YAP transcriptional activity [112]. Another study found that resveratrol treatment
suppressed the expression of nutrient-deprivation autophagy factor-1 (NAF-1) in pancreatic cancer
cells by inducing ROS accumulation. This led to the activation of nuclear factor erythroid 2-related
factor 2 (Nrf2) signaling, and that these mechanistic modifications resulted in improved sensitivity
of pancreatic cancer cells to gemcitabine [113]. Not only can resveratrol enhance chemotherapeutic
response, but a recent study done by Zhou et al. showed that it can also reverse the stemness of
pancreatic cancer cells induced by gemcitabine [114]. In this study, resveratrol treatment was found to
enhance sensitivity to gemcitabine by inhibiting lipid synthesis via SREBP1, which limited the sphere
formation ability and suppressed gemcitabine-induced stemness, as well as the expression of CSC
markers [114]. Overall, these findings indicated resveratrol’s response in augmenting chemotherapy
efficacy against pancreatic cancer due to its diverse targetability of signaling pathways.
5. Apigenin
Malignant cells require nutrients such as glucose and amino acids to support their sustained
growth, and in their absence, tumor cells scavenge extracellular proteins such as albumin for their
survival [115,116]. To transport the specific nutrients, cancer cells acquire transport mechanisms,
such as glucose transporters for the transport of glucose, etc., [117,118]. Therefore, agents that can
inhibit such transporters or their metabolism are being explored as promising therapeutic agents for
cancer intervention. Figure 4 depicts the chemoprevention mechanisms of apigenin and its ability to
enhance the sensitivity or efficacy of chemotherapeutic agents. In one study, the effect of apigenin was
evaluated on GLUT1 expression, and the mechanisms regulating its expression were determined in
CD18 and S2-013 human pancreatic cancer cell lines [119]. The studies demonstrated that apigenin
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inhibited GLUT1 expression and glucose uptake in a time- and dose-dependent manner, similar to
that observed by PI3K inhibitors, suggesting that the apigenin effects were mediated via the inhibition
of PI3K signaling [119]. Studies by the same group later reported that hypoxic conditions can also
upregulate the protein and mRNA expression of GLUT1, as well as hypoxia-related HIF-1α and VEGF,
which were reversed by apigenin in CD18 and S2-013 pancreatic cancer cell lines [120]. These findings
could offer additional mechanisms that apigenin can target in both normoxic and hypoxic conditions
for pancreatic cancer chemoprevention.
Antioxidants 2020, 9, x FOR PEER REVIEW 11 of 21 
determined in CD18 and S2-013 human pancreatic cancer cell lines [119]. The studies demonstrated 
that apigenin inhibited GLUT1 expression and glucose uptake in a time- and dose-dependent 
manner, similar to that observed by PI3K inhibitors, suggesting that the apigenin effects were 
mediated via the inhibition of PI3K signaling [119]. Studies by the same group later reported that 
hypoxic conditions can also upregulate the protein and mRNA expression of GLUT1, as well as 
hypoxia-related HIF-1α and VEGF, which were reversed by apigenin in CD18 and S2-013 
pancreatic cancer cell lines [120]. These findings could offer additional mechanisms that apigenin 




Figure 4. Mechanisms of apigenin-mediated chemopreventive effects as well as augmenting the 
sensitivity of chemotherapeutic agents against pancreatic cancer. The sign  denotes increase or 
activation,  decrease expression or downregulation,    inhibition or suppression, and      
induction.   
  
In another report, the authors determined the interaction of apigenin with GSK3β [121]. 
Molecular docking studies predicted that apigenin binds within the GSK3β cavity with low 
interaction energies, which leads to the inhibition of its enzymatic activity [121]. Similar results were 
observed with other flavonoids such as quercetin and luteolin, indicating their potential in targeting 
GSK3β signaling to suppress pancreatic cancer. Apigenin has also been shown to induce G2/M cell 
cycle arrest and apoptosis in BxPC-3 and PANC-1 pancreatic cancer cell lines via targeting 
GSK3β/NF-kB signaling cascade [122]. Increased expression of cytokines (including the IL17 family, 
LTA and INFB1) was correlated with increased apigenin-induced apoptosis [122]. Given the critical 
roles of NF-kB in cancer progression, studies by Wu et al. determined the regulatory mechanism of 
NF-kB in the context of apigenin [123]. Apigenin treatment decreased cell survival and increased 
apoptosis of AsPC-1, PANC-1 and MiaPaCa-2 pancreatic cancer cell lines through the inhibition of 
tumor necrosis factor-alpha (TNFα)-induced DNA binding (p65 and p50 subunits), resulting in 
reduced transcriptional activities of NF-kB [123]. Decreased NF-kB activity was associated with IkBα 
degradation, reduced expression, and activation of upstream IKK (α and β subunits), and reduced 
NF-kB nuclear translocation [123]. Notably, the NF-kB inhibitor Bay11-7082 enhanced the 
chemosensitivity of apigenin, and IKKβ overexpression attenuated apigenin-induced decreased cell 
survival. Importantly, suppression of AsPC-1 tumor growth by apigenin was also correlated with 
decreased protein expression and phosphorylation of IKKα/β and increased apoptosis [123]. These 
findings indicated that apigenin targets IKK-mediated NF-kB activation to inhibit pancreatic cancer 
growth. From these studies, it can be postulated that apigenin could be explored in combination with 
the pharmacological inhibitors of these pathways/targets in widely used transgenic experimental 
pancreatic cancer models. 
Figure 4. Mechanisms of apigenin-mediated chemopreventive effects as well as augmenting the
sensitivity of chemotherapeutic agents against pancreatic cancer. The sign
Antioxidants 2020, 9, x FOR PEER REVIEW 4 of 21 
Figure 2. Mechanisms of quercetin-mediated chemopreventive effects as well as augmenting the 
sensitivity of chemotherapeutic agents against pancreatic cancer. The sign  denotes increase or 
activation and     den tes inhibition or suppression. 
An active area of research in preclinical models is to determine whether the bioavailability of 
orally or intra eritoneally administered quercetin results in sufficient systemic concentration  that 
could result in a sustained anti-tumoral activity. In the intestine, quercetin undergoes hydrolysis by 
lactase phlorizin hydrolase, resulting in subsequent diffusion as quercetin aglycones are actively 
transported by sodium-dependent glucose transporter, and then, subsequent deglycosylation by 
cytosolic β-glucosida e [54]. Studies by Zhang et al. evaluated the uptake of quercetin in MiaPaCa-2 
pancreatic cancer cells in vitro, as well as its in vivo distribution in murine pancreatic tumor 
xenografts, plasma, lung, liver and pancreas [55]. The authors demonstrated that following treatment 
with 30 µM quercetin, it quickly accumulates in MiaPaCa-2 cells at nmol/mg protein concentration 
within 30 min, b t its level d creases gradually in a time-depende t manner [55]. Simil rly, nude 
mice harboring orthotopic MiaPaCa-2 tumor xenografts, and fed with 0.2% or 1% or 5% quercetin in 
an AIN93G-based diet for a period of 6–8 weeks, have found to exhibit varying levels of quercetin 
and its metabolite isorhamnetin in plasma and tumors, as well as in liver, lung and pancreas, which 
indicates its effective absorption [55]. While cotreatment of gemcitabine (120 mg/kg per mouse, i.p.) 
with quercetin (1%) has been found to result in significantly decreased growth of pancreatic tumors, 
gemcitabine reduced quercetin absorption in the circulatory system and liver, but not in other tissues 
[55]. These studies suggested that quercetin gets readily etabolized and bioavailable to exert a 
systemic anti-tumoral effect as well as augments chemotherapy efficacy. However, further studies 
are warranted to verify whether or not quercetin can also enhance the metabolism and absorption of 
chemotherapy agents. 
Several cellular mechanisms by which quercetin treatment inhibits the growth of pancreatic 
cancer cell lines in in vitro and in vivo models, have been identified. The authors have also explored 
the cellular model systems to test the sensitivity or resistance to agents, to further define the 
translational significance of quercetin to be used in combination treatment approaches for pancreatic 
cancer. In o e such study, Borska et al. determined the effects f quercetin on the dau orubi in 
sensitive EPP85-181P cell line, as well as the daunorubicin resistant EPP85-181RDB cell line [56]. 
Quercetin exposure was found to reduce cell proliferation and increase apoptosis in both the cell lines 
in a dose-dependent manner. Importantly, quercetin combined with daunorubicin induced 
synergistic effects in daunorubicin-sensitive cells, and also, sensitized the daunorubicin-resistant cells 
to daunorubicin cytotoxic effects [56]. Another report by the same group later identified the role of 
P-glycoprotein (ABCB1), one of the ABC transporters reported to induce chemoresistance via its 
denotes increase or
activation,
Antioxidants 2020, 9, x FOR PEER REVIEW 11 of 21 
inhibited GLUT1 expr ssion and glucose up ake in a time- and dose-dependent manner, similar to 
that observed by PI3K inhibitors, suggesting that the apigenin effects were mediated via the 
inhibition of PI3K signaling [119]. Studies by the same group later reported that hypoxic conditions 
can also upregulate the protein and mRNA expression of GLUT1, as well as hypoxia-related HIF-1α 
and VEGF, which were reversed by apigenin in CD18 and S2-013 pancreatic cancer cell lines [120]. 
These findings could offer additional mechanisms that apigenin can target in both normoxic and 
hypoxic conditions for pancreatic cancer chemoprevention. 
 
Figure 4. Mechanisms of apigenin-mediated chemopreventive effects as well as augmenting the 
sensitivity of chemotherapeutic agents against pancreatic cancer. The sign  denotes increase or 
activation,  decrease expression or downregulation,    inhibition or suppression, and      
induction.   
  
In another report, the authors determined the interaction of apigenin with GSK3β [121]. 
Molecular docking studies predicted that apigenin binds within the GSK3β cavity with low 
interaction energies, which leads to the inhibition of its enzymatic activity [121]. Similar results were 
observed with other flavonoids such as quercetin and luteolin, indicating their potential in targeting 
GSK3β signaling to suppress pancreatic cancer. Apigenin has also been shown to induce G2/M cell 
cycle arrest and apoptosis in BxPC-3 and PANC-1 pancreatic cancer cell lines via targeting 
GSK3β/NF-kB signaling cascade [122]. Increased expression of cyt kine  (including the IL17 family, 
LTA and INFB1) was correlated with increased apigenin-induced apoptosis [122]. Given the critical 
roles of NF-kB in cancer progression, studies by Wu et al. determined the regulatory mechanism of 
NF-kB in the context of apigenin [123]. Apigenin treatment decreased cell survival and increased 
apoptosis of AsPC-1, PANC-1 and MiaPaCa-2 pancreatic cancer cell lines through the inhibition of
tumor necrosis factor-alpha (TNFα)-induced DNA binding (p65 and p50 subunits), resulting in 
reduced transcriptional activities of NF-kB [123]. Decreased NF-kB activity was associated with IkBα 
degradation, reduced expression, and activation of upstream IKK (α and β subunits), and reduced 
NF-kB nuclear tra slocation [123]. Notably, the NF-kB inhibitor B y11-7082 enhanced the 
chemosensitivity of apigenin, and IKKβ overexpression attenuated apigenin-induced decreased cell 
survival. Importantly, suppression of AsPC-1 tumor growth by apigenin was also correlated with 
decreased protein expression and phosphorylation of IKKα/β and increased apoptosis [123]. These 
findings indicated that apigenin targets IKK-mediate  NF-kB activation to inhibit pancreatic cancer 
growth. From these studies, it can be postulated that apigenin could be explored in combination with 
the pharmacological inhibitors of these pathways/targets in widely used transgenic experimental 
pancreatic cancer models. 
5.1. Other Cellular Targets of Apigenin 
decrease expression or downregulation,
Antioxidants 2020, 9, x FOR PEER REVIEW 11 of 21 
i hibited GLUT1 expression and glucose uptake in a time- and dose-dependent manner, similar to 
that observed by PI3K inhibitors, suggesting that the apigenin effects were mediated via the 
inhibition of PI3K signaling [119]. Studies by the same group later reported that hypoxic conditions 
can also upregulate the protein and mRNA expression of GLUT1, as well as hypoxia-related HIF-1α 
and VEGF, hich were reversed by apigenin in CD18 and S2-013 pancreatic cancer cell lines [120]. 
These findings could offer additional mechanisms that apigenin can target in both normoxic and 
hypoxic conditions for pancreatic cancer chemoprevention. 
 
Figure 4. Mechanisms of apigenin- ediated chemopreventive effects as well as augm nting th  
sensitivity of chemotherapeutic agents against p creatic ca cer. The sign  denotes increase or 
activation,  decrease expression or downregulation,    inhibition or suppression, and      
induction.   
  
In another rep rt, the author  determined he inter tion of apigenin with GSK3β [121]. 
Molecular docking studies predicted that apigenin binds within the GSK3β cavity with low 
interaction energies, which leads to the inhibition of its enzymatic ctivity [121]. Similar results were 
observed with other flav noids s h as querc tin and luteolin, indicating their potential in target g 
GSK3β signaling to suppress pancr atic cancer. Apigenin has also been sh wn o induce G2/M cell 
cycle arrest and apoptosis in BxPC-3 and PANC-1 pancreatic cancer cell lines via targeting 
GSK3β/NF-kB signaling cascade [122]. I creased expression of cytokines (including the IL17 family, 
LTA and INFB1) was correlated with increa ed apig nin-induced apoptosis [122]. Giv  the critical 
roles of NF-kB in cancer progression, studies by Wu et al. dete mi ed the regulatory mechanism of 
NF-kB in the context of apigenin [123]. Apigenin treatment decreased c ll s rvival and ncreased 
apoptosis of AsPC-1, PANC-1 nd MiaPaCa-2 pa creatic cancer cell line  through the inhibitio  of 
tumor necrosis factor-alpha (TNFα)-induced DNA binding (p65 and p50 subunits), resulting in 
reduced transcriptional activities of NF-kB [123]. Decreased NF-kB activity was associ t  with IkBα 
degradation, reduced expression, and activation of upstream IKK (α and β subunits), a  reduced 
NF-kB nuclear translocation [123]. Notably, the NF-kB inhibi or Bay11-7082 enhance  the 
chemosensitivity of apigenin, and IKKβ over xpression ttenuat d apig nin-induced decreased cell 
survival. Importantly, suppression of AsPC-1 tumor gr wth by apige in was also correlated with 
decreased protein expression nd phosphorylation of IKKα/β and increased apoptosis [123]. These 
fi dings indicated that apig nin targets IKK-mediated NF-kB activation to inhibit p creatic cance  
growth. From these studies, it ca  be postulated that apigenin could be xplore  i  combination with
the pharmacological inhibitors of th se pathways/targe s in widely used transgenic experimen al 
pancreatic cancer models. 
5.1. Other Cellular Targets of Apigenin 
inhibition or suppression, and
Antioxidants 2020, 9, x FOR PEER REVIEW 11 of 21 
inhibited GLUT1 expression and glucose uptake in a time- and dose-dependent manner, similar to 
that observed by PI3K inhibitors, suggesting that the apigenin effects were mediated via the 
inhibition of PI3K signaling [119]. Studies by the same group later reported that hypoxic conditions 
can also upregulate the protein and mRNA expression of GLUT1, as well as hypoxia-related HIF-1α 
and VEGF, which were reversed by apigenin in CD18 and S2-013 pancreatic cancer cell lines [120]. 
These findings could offer additional mechanisms that apigenin can target in both normoxic and 
hypoxic conditions for pancreatic cancer chemoprevention. 
 
Figure 4. Mechanisms of apigenin-mediated chemopreventive effects as well as augmenting the 
sensitivity of chemotherapeutic agents against pancreatic cancer. The sign  denotes increase or 
activation,  decrease expression or downregulation,    inhibition or suppression, and      
induction.   
  
In an ther report, the authors determined the interaction of apigenin with GSK3β [121]. 
Molecular docking studies predicted that apigenin binds within the GSK3β cavity with low 
interaction energies, which leads to the inhibition of its enzymatic activity [121]. Similar results were 
observed with other flavonoids such as quercetin and luteolin, indicating their potential in targeting 
GSK3β signaling to suppress pancreatic cancer. Apigenin has also been shown to induce G2/M cell 
cycle arrest and apoptosis in BxPC-3 and PANC-1 pancreatic cancer cell lines via targeting 
GSK3β/NF-kB signaling cascade [122]. Increased expression of cytokines (including the IL17 family, 
LTA and INFB1) was correlated with increased apigenin-induced apoptosis [122]. Given the critical 
roles of NF-kB in cancer progression, studies by Wu et al. determined the regulatory mechanism of 
NF-kB in the context of apigenin [123]. Apigenin treatment decreased cell survival and increased 
apoptosis of AsPC-1, PANC-1 and MiaPaCa-2 pancreatic cancer cell lines through the inhibition of 
tumor necrosis factor-alpha (TNFα)-induced DNA binding (p65 and p50 subunits), resulting in 
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chemosensitivity of apigenin, and IKKβ overexpression attenuated apigenin-induced decreased cell 
survival. Importantly, suppression of AsPC-1 tumor growth by apigenin was also correlated with 
decreased protein expression and phosphorylation of IKKα/β and increased apoptosis [123]. These 
findings indicated that apigenin targets IKK-mediated NF-kB activation to inhibit pancreatic cancer 
growth. From these studies, it can be postulated that apigenin could be explored in combination with 
the pharmacological inhibitors of these pathways/targets in widely used transgenic experimental 
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5.1. Other Cellular Targets of Apigenin 
induction.
In anoth por , the authors deter ined the interactio of apigenin with GSK3β [121]. Molecular
docking studies predicted that apigenin binds within t e GSK3β cavity ith low interaction energies,
which leads to the inhibition of its enzymatic activity [121]. Similar results were observed with other
flavonoids such s quercetin a d luteolin, i dicating their p te ial n target g GSK3β signaling to
suppress pancreatic cancer. Apigenin has also been shown to induce G2/M cell cycle arrest and apoptosis
in BxPC-3 and PANC-1 pa cr atic canc r cell li s via argeting GSK3β/NF-kB signaling cascade [122].
Increased expression of cytokines (including the IL17 family, LTA and INFB1) was correlated with
increased apigenin-induce apoptosis [122]. Given th criti al roles of NF-kB in cance pro ression,
studies by Wu et al. determine the regulatory m chanism of NF-kB in the co text of apigenin [123].
Apigenin treatment decreased c ll survival and increased apoptosis of AsPC-1, PANC-1 and MiaPaCa-2
pancreatic cancer cell li es through th in ibition f tumor necrosis fa tor-alph (TNFα)-induced
DNA binding (p65 and p50 subunits), resulting in reduced transcriptional activities of NF-kB [123].
Decr ased NF-kB activity was ass ci ed with IkBα degra tion, reduced expression, and activation of
upstream IKK (α and β subunits), and reduced NF-kB nuclear translocation [123]. Notably, the NF-kB
inhibitor B y11-7082 enhanced the chemosensitivity of apigeni , and IKKβ overexpression attenuated
apigenin-induced decreased cell survival. Imp rtantly, suppression of AsPC-1 tumor growth by
apigenin was also correlated with decreased protein expression and phosphorylation of IKKα/β
and increased apoptosis [123]. These findings indicated that apigenin target IKK-mediat d NF-kB
activation to inhibit pancreatic cancer growth. From these studies, it can be postulated that apigenin
could be explored in c mbination with th pharmacological inhibitors of thes pathways/targets in
widely used transgenic experimental pancreatic cancer models.
5.1. Other Cellular Targets of Apigenin
Multiple studies have also defined other mechanisms of apigenin-mediated chemopreventive
effects in pancreatic cancer models. In one study, apigenin-induced growth suppression and increased
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apoptosis were found to be mediated by post-translational modification, nuclear translocation, and DNA
binding of p53, as well as p21 and PUMA upregulation in BxPC-3 and MiaPaCa-2 cell lines with
mutated p53 expression [124]. However, further studies demonstrated p53 DNA binding activity and
transcriptional activity were not necessary for the observed ability of apigenin to suppress cell growth
or increase apoptosis. Additional confirmatory studies suggested that the in vitro and in vivo effects of
apigenin could be mediated via the augmentation of transcription-independent p53 functions, despite
its deactivating mutations [124]. Importantly, another group demonstrated differential cytotoxic
effects of apigenin in PANC-1 and PaCa44 pancreatic cancer cell lines, which harbor different p53
mutations [125]. The PANC-1 cell line exhibited greater apigenin cytotoxicity compared to the PaCa44
cell line, which was dependent on increased induction of intracellular ROS/decreased antioxidant
defenses, mutant (mut) p53 reduction, as well as inhibition of mTOR and heat shock protein 90
(HSP90) [125]. These findings suggested that an interplay between mTOR-HSP90-mut p53-p62-NRF2
mediates apigenin chemoresistance in p53 mutated pancreatic cancer.
5.2. Apigenin Effects on Chemotherapy Efficacy
In addition to exerting cancer chemoprevention effects, apigenin has also been tested for its efficacy
in enhancing the efficacy of anticancer agents. Notably, the combination of apigenin with gemcitabine
has been shown to cause enhanced cytotoxic effects in in vitro and in vivo pancreatic cancer models
compared to apigenin or gemcitabine alone [126]. These effects were found to be mediated due to the
inhibition of NF-kB and Akt activation [126]. Similarly, another study also reported that apigenin
and gemcitabine combination resulted in higher cytotoxic effects than individual treatment [127].
Mechanistically, the enhanced effects of combination therapy were found to be mediated via S and G2/M
cell cycle arrest, and inhibition of Akt signaling leading to increased apoptosis in CD18 and AsPC-1
pancreatic cancer cell lines [127]. Another study examined whether apigenin and other related flavones
could overcome resistance to apoptosis in response to the treatment with TRAIL [128]. This was
done using the TRAIL-resistant human T cell leukemia virus type 1 (HTLV-1)-associated adult T cell
leukemia (ATL) cellular model [128]. Mechanistic studies demonstrated that apigenin downregulates
the protein expression of c-FLIP via inhibiting Mdm2 that antagonizes p53. This upregulated p53
activity as well as the expression of its downstream target TRAIL-receptor 2, which in turn augmented
TRAIL-induced apoptosis [128]. Similar effects were observed in multiple cancer cell lines, including
Capan-1 pancreatic cancer cells, indicating the potential use of natural flavone compounds such as
apigenin as an adjuvant to improve the efficacy of anticancer agents such as TRAIL.
6. Luteolin
Another dietary polyphenol flavonoid that has been extensively studied in cancer models
including pancreatic cancer is luteolin. Multiple studies have explored the role and chemopreventive
mechanisms of luteolin using various in vitro and in vivo models of pancreatic cancer. Figure 5 depicts
the chemoprevention mechanisms of apigenin and its ability to enhance the sensitivity or efficacy of
chemotherapeutic agents. A study led by Cai et al. demonstrated that luteolin treatment inhibits the
proliferation of PANC-1, CoLo-357 and BxPC-3 pancreatic cancer cell lines via inducing apoptosis [129].
These effects were mediated through increased caspase-3 and poly ADP-ribose polymerase (PARP)
cleavage associated with increased expression of pro-apoptotic Bax, and decreased expression of
anti-apoptotic Bcl-2 proteins [129]. Using the HUVEC cell line, a widely used model to study tubule
formation or angiogenesis, the authors demonstrated that luteolin inhibited HUVEC cell proliferation
and capillary formation via its ability to suppress the transcriptional activity of NF-kB, resulting in
reduced VEGF expression and secretion [129]. These findings indicated that luteolin inhibits angiogenic
as one of the mechanisms to induce apoptosis in pancreatic cancer cells.
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An active area of research in preclinical models is to determine whether the bioavailability of 
orally or intraperitoneally administered quercetin results in sufficient systemic concentrations that 
could result in a sustained anti-tumoral activity. In the intestine, quercetin undergoes hydrolysis by 
lactase phlorizin hydrolase, resulting in subsequent diffusion as quercetin aglycones are actively 
transported by sodium-dependent glucose transporter, and then, subsequent deglycosylation by 
cytosolic β-glucosidase [54]. Studies by Zhang et al. evaluated the uptake of quercetin in MiaPaCa-2 
pancreatic cancer cells in vitro, as well as its in vivo distribution in murine pancreatic tumor 
xenografts, plasma, lung, liver and pancreas [55]. The authors demonstrated that following treatment 
with 30 µM que cetin, it quickly accumulates in MiaPaCa-2 ells at nmol/mg protein concentration 
within 30 min, but its level decreases gradually in a time-dependent manner [55]. Similarly, nude 
mice harboring orthotopic MiaPaCa-2 tumor xenografts, and fed with 0.2% or 1% or 5% quercetin in 
an AIN93G-based diet for a period of 6–8 weeks, have found to exhibit varying levels of quercetin 
and its metabolite isorhamne in in plasma and tumors, as well as in liver, lung and pancreas, which 
indicates its effective absorption [55]. While cotreatment of gemcitabine (120 mg/kg per mouse, i.p.) 
with quercetin (1%) has been found to result in significantly decreased growth of pancreatic tumors, 
gemcitabine reduced quercetin absorption in the circulatory system and liver, but not in other tissues 
[55]. These studies suggested that quercetin gets readily metabolized and bioavailable to exert a 
systemic anti-tumoral effect as well as augments chemotherapy efficacy. However, further studies 
are warranted to verify whether or not quercetin can also enhance the metabolism and absorption of 
chemotherapy agents. 
Several cellular mechanisms by which quercetin treatment inhibits the growth of pancreatic 
cancer cell lines in in vitro and in vivo models, have been identified. The authors have also explored 
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Quercetin exposure was found to reduce cell proliferation and increase apoptosis in both the cell lines 
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Molecular docking studies predicted that apigenin binds within the GSK3β cavity with low 
interaction energies, which leads to the inhibition of its enzymatic activity [121]. Similar results were 
observed with other flavonoids such as quercetin and luteolin, indicating their potential in targeting 
GSK3β signaling to suppress pancreatic cancer. Apigenin has also been shown to induce G2/M cell 
cycle arrest and apoptosis in BxPC-3 and PANC-1 pancreatic cancer cell lines via targeting 
GSK3β/NF-kB signaling cascade [122]. Increased expression of cytokines (including the IL17 family, 
LTA and INFB1) was correlated with increased apigenin-induced apoptosis [122]. Given the critical 
roles of NF-kB in cancer progression, studies by Wu et al. determined the regulatory mechanism of 
NF-kB in the context of apigenin [123]. Apigenin treatm nt decr ased cell survival and increased 
apoptosis of AsPC-1, PANC-1 and MiaPaCa-2 pancreatic cancer cell lines through the inhibition of 
tumor necrosis factor-alpha (TNFα)-induced DNA binding (p65 and p50 subunits), resulting in 
reduced transcriptional activities of NF-kB [123]. Decreased NF-kB activity was associated with IkBα 
degradation, reduced expression, and activation of upstream IKK (α and β subunits), and reduced 
NF-kB nuclear translocation [123]. Notably, the NF-kB inhibitor Bay11-7082 enhanced the 
chemosensitivity of apigenin, and IKKβ overexpression attenuated apigenin-induced decreased cell 
survival. Importantly, suppression of AsPC-1 tumor growth by apigenin was also correlated with 
decreased protein expression and phosphorylation of IKKα/β and increased apoptosis [123]. These 
findings indicated that apigenin targets IKK-mediated NF-kB activation to inhibit pancreatic cancer 
growth. From these studies, it can be postulated that apigenin could be explored in combination with 
the pharmacological inhibitors f these pathways/targets in widely used t ansgenic experimental 
pancreatic cancer models. 
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6.1. Other Cellular Targets of L teolin
Notably, i creased Bcl-2 expres i n has be n implicated in tumor progressi n, and the induction of
chemoresistance in cancer mod ls, as well as corr lated with poor prognosis in cancer patie ts [130–134].
Luteolin treatment has been found to induce apoptosis in Bcl-2 overexpressing SW1990 pancreatic
cancer cells via inhibiti g Bcl-2 expression in a dose-dependent manner [135]. Ce lular thermal shift
and competitive binding assays revealed that luteolin irectly binds to Bcl-2 and displaces BAX from
its hy rophobic left, resulting n mitoc d i l p rmeabilization leading to a optosi [135]. Similarly,
luteolin treatment resulted in a significant red ctio in SW1990 tum xenogra t growth, indicating its
potential in targeting Bcl-2 ov rexpressing pa creatic cancer [135].
Another study determined the mechanis s of l teolin in regulatin EMT and cancer invasiveness
using PANC-1 and SE1990 pancreatic ca cer cell lines [136]. Luteolin treatment in a dose-dependent
manner inhibited EMT, protein expr ssion of MMPs (i.e., MMP2/7/9), and STAT3 sig aling, as well
as decreased the invasiveness of pancre tic anc r cells [136]. Treatment with IL-6, an upstream
regulator of STAT3, e han ed EMT, MMP secretion and STAT3 activity in a process blocked by
luteolin, indicating its chemopr ventiv pote tial [136]. Over ll, thes fi dings also sugg st that
pharmacological inhibitors of these pathways could be explored in combination with luteolin to achieve
enhance h mopr v ntive ffects in pan reati cancer models.
6.2. Luteolin Effects on Chemotherapy Efficacy
Given luteolin’s beneficial effects against pancreatic cancer, studies by Johnson et al. eval ate its
combinatio with hemotherap utic gents sing a in v tro BxPC-3 pancreatic can er ll model [137].
While concurrent treatment of lu eolin in combination with either 5FU or gemcitabine result in
relativ ly less cytotoxic effe ts, pretreatment with luteolin sensitized he cells to the growth inhibitor
effects of th se hemo rapeutic agents. These effects were mediated via decr ased expression of
GSK3β and NF-kB and i creased the release of t e pro-apoptotic cytochrome c protein [137]. Similar
effects were observed with another flavonoid apigenin. Another study by the same group tested the
effects of luteolin in combination with gemcitabine using an in vivo orthotopic model of pancreatic
cancer [138]. The authors demonstrated that combination therapy with luteolin and gemcitabine
resulted in a significant reduction in tumor growth compared to either the control group, or the two
single-agent treatment groups [138]. Mechanistically, inhibition of the K-ras/GSK3β/NF-kB pathway
by the luteolin + gemcitabine combination therapy was found to correlate with reduced tumor cell
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proliferation and increased apoptosis as confirmed by increased caspase-3 activation and decreased
Bcl-2/Bax ratio and cytochrome c release [138]. These findings indicated that luteolin targets similar
signaling pathways both in the in vitro and in vivo models, to inhibit growth or enhance chemotherapy
sensitivity against pancreatic cancer.
7. Conclusions
Numerous studies indicate a role for antioxidant-enriched polyphenols in regulating the growth
and metastasis of experimental pancreatic cancer models. While data regarding the safety and benefits
of these polyphenols used during cancer treatment are largely absent, preliminary cell line and animal
studies suggest a potential benefit. Importantly, the potential of these polyphenols in enhancing the
efficacy of standard chemotherapeutic agents, and other natural compounds against experimental
pancreatic cancer provide a rationale for their exploration in clinical settings. As large percentage
of cancer patients undergoing active treatments use antioxidant-enriched compounds of all natural
sources, and not all are likely to be beneficial; further preclinical and clinical studies are needed to
establish the use of such polyphenols as adjuvants, to determine their optimal doses and timings for
the management of cancer in combination with therapeutic regimens. Importantly, more preclinical
studies determining the pharmacokinetic and pharmacodynamic profiles of these polyphenols are
needed to assess the bioavailability of related compounds/metabolites. These studies would help
optimize the dosing regimens of these natural polyphenols to evaluate their anti-tumor efficacy alone
and in combination with therapeutic agents. Furthermore, bioinformatics studies are needed to predict
the targets of these polyphenols so their pharmacological inhibitors could be tested to verify the
mechanisms in cellular and preclinical studies.
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